Pharmaceutical industry news

Keeps Biopharma’s Idetrexed wins Korean phase 2 IND approval

Pharmaceutical firm Boryung to split-off sales, marketing divisions

Purity with purpose: Clariant Health Care raises the bar for pharmaceutical excipients

Gemeinsam für ein gesundes Uniklinikum

India Could Get Its First Indigenous Dengue Vaccine by 2027: ICMR DG Reveals Timeline

ETFs Investing in Mochida Pharmaceutical Co., Ltd. Stocks

Esophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Esophageal pH Monitoring Capsule Delivery Device

The Medtronic and Given Imaging Bravo CF esophageal pH monitoring capsule can fail to attach to the...

Nearly 10,000 patients reveal what works best for knee arthritis pain relief

Tiny cell “antennas” may help explain why some babies are born with heart defects

AI-native biotech Yudao Bio raises $30M Series C

Plague was killing entire families thousands of years before the Black Death

Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Plays

東北大学ジャパンバイオデザインプログラム 2027年度フェロー募集のお知らせ

Flinders’ nuclear courses to power South Australia’s future AUKUS workforce

5 Best Biotech Stocks for 2026 and How to Invest

test Seoul biotech startups enter Boston pipeline through LabCentral

Navigating Biopharma Complexity: Why Long-Term Partnerships Matter

Propriedade intelectual e eficiência regulatória como motores do bem-estar regional

Cancer Detection Biotech Lodges Patent Suit Against Rival

Intellectual property and regulatory efficiency as drivers of regional well-being

Report from the FDA’s hearing on psychedelic drugs

BSR, SDIC Biotech seek cooperation on ethanol, biofuels

Swiss biotech giant Lonza breaks ground on major Bend expansion

Propiedad intelectual y eficiencia regulatoria como motores del bienestar regional

AstraZeneca filed Form 6-K

Novo Nordisk filed Form 6-K

GSK filed Form 6-K

Engineering botulinum neurotoxin into anti-cancer agents

A hierarchical genomic framework associated with response to BRAF-directed therapy across solid tumors

Intracranial recordings in humans reveal differential contributions of medial and lateral orbitofrontal cortex to approach–avoidance decision-making

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

Beyond the breakthrough for RAS-driven cancers

On-premise medical AI agents for reliable clinical decision-making

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial

A versatile nanopore identifies four classes of analytes simultaneously

Ensuring safety and accountability in China’s biomedical translation system

Quality control of glycogen through direct ubiquitylation by RNF213

Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance

Why Nepal floods resulted in a disaster even after satellites spotted danger

Why the NIH must resist the metrics trap

Make AI traceable before it shapes global climate assessments

A wake-up call: diversify global research funding

Global inequality panel is a chance for research to change lives

Cities and countryside are intimately linked — green initiatives must recognize that

Underground hydrogen could spur a green-energy revolution — if companies can find it

CRISPR crops are coming to Europe — why bolder would be better

The geometric genius of René Descartes

natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26

natco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27

natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26

natco receives tentative approval for olaparib tablets from the united states food and drug administration u s fda

natco receives approval from central drug standard control organisation cdsco for semaglutide in india

natco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49

natco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limited

natco pharma limited api unit in chennai receives establishment inspection report eir from u s fda

natco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unit

natco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290

natco announces launch of pomalidomide capsules generic of pomalyst in the u s market

natco and lupin receive approval from u s fda for eribulin mesylate injection

investment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limited